The laboratory assessment of lipid disorders

Show simple item record Vermaak, William J.H. 2007-10-05T13:19:26Z 2007-10-05T13:19:26Z 2003-07
dc.description.abstract The older 'traditional' lipid guidelines have placed undue emphasis on individually high-risk factors such as cholesterol. The aim of the TC cut-off points of 5.2 mmol/l and 6.2 mmol/l was to identify as many subjects as possible who have borderline to high risk and high risk for CHD respectively. This approach created the impression that all subjects with serum cholesterol greater than 5.2 or 6.2 mmol/l are at a higher or high risk for CHD and it ignored the fact that a cluster of coexisting, mildly abnormal risk factors may confer a much higher risk on an individual than only one very high risk factor. The latest guidelines suggest that these cut-off points should no longer be interpreted in isolation but rather against the background of the global CHD risk of a patient. This will avoid unnecessary treatment of patients who are not really at risk or alternatively identify patients who require aggressive lipid-lowering therapy even though their serum TC or LDLC may be only moderately elevated or may indeed be within the so-called desirable range. The repertoire of laboratory investigations to fully assess the patient's total risk for CHD needs to be done in a logical progression in order to answer the following 5 crucial clinical questions: Which patients should be targeted for lipid screening ? What variables can influence the validity of the results that need to be controlled ? What laboratory tests should be done on them ? What further laboratory tests are required in patients whose screening results justify possible intervention ? What laboratory tests are indicated in monitoring patients who receive lipidlowering drugs? The subsequent management of the dyslipidaemic patient will depend on the nature and severity of the disorder, i.e. predominant hypercholesterolaemia, predominant hypertriglyceridaemia or a combined disorder. More complex disorders such as type III (broad B band disease) and atypical presentations or clinical syndromes should be referred to specialist lipid clinics for further investigations. Lipid guidelines and risk assessment algorithms should be used to supplement, not replace clinical judgement. en
dc.format.extent 409249 bytes
dc.format.mimetype application/pdf
dc.identifier.citation Vermaak, WJH 2003, 'The laboratory assessment of lipid disorders', CME, vol. 21, no. 7, pp.391-396. [] en
dc.identifier.issn 0256-2170
dc.language.iso en en
dc.publisher Health and Medical Publishing Group en
dc.rights Health and Medical Publising Group en
dc.subject Lipid disorders en
dc.subject Risk assessment en
dc.subject Laboratory diagnosis en
dc.subject Hyperlipidaemia en
dc.subject Dyslipidaemia en
dc.subject.lcsh Coronary heart disease
dc.subject.lcsh Lipids--Research
dc.subject.lcsh Medical screening
dc.subject.lcsh Hypercholesteremia
dc.subject.lcsh Hypertriglyceridemia
dc.title The laboratory assessment of lipid disorders en
dc.type Article en

Files in this item

This item appears in the following Collection(s)

Show simple item record